Abstract
Nine new oxazolinyl derivatives of [17(20)E]-21-norpregnene, differing in the structure of steroid moiety, were investigated for their potency to inhibit the CYP17A1 catalytic activity, as well as growth and proliferation of LNCaP and PC-3 prostate carcinoma cell lines. The activity of one of the investigated compounds, 2´-{[(E)3β-hydroxyandrost-5-en-17-ylidene]methyl}-4´,5´-dihydro-1´,3´-oxazole (1), was found to be comparable with that of Abiraterone, a known inhibitor of CYP17A1 used for treatment of prostate cancer. A model of the interaction of oxazoline 1 with the active site of CYP17A1 was constructed by the molecular dynamics method. A correlation was found between the structure and the biological activity in the series of [17(20)E]-21-norpregnene oxazolinyl derivatives.
Similar content being viewed by others
References
Cytochrome P-450: structure, mechanism, and biochemistry, 3rd ed., Ed. P. R. Ortiz de Montellano, Kluwer Academic/Plenum Press, New York, 2005, 690 pp.
M. Akhtar, J. N. Wright, in Advances in Experimental Medicine and Biology 851, Eds. E. G. Hrycay, S. M. Bandiera, Springer, Cham–Heidelberg–New York–Dortrecht–London, 2015, p.107.
F. K. Yoshimoto, R. J. Auchus, J. Steroid Biochem. Mol. Biol., 2015, 151,52.
A. B. Alex, S. K. Pal, N. Agarwal, Ther. Adv. Med. Oncol., 2016, 8,267.
L. Gomez, J. R. Kovac, D. J. Lamb, Steroids, 2015, 95,80.
R. D. Bruno, V. C. Njar, Bioorg. Med. Chem., 2007, 15, 5047.
E. Baston, F. R. Leroux, Rec. Pat. Anticancer Drug Discov., 2007, 2,31.
C. P. Owen, Anticancer Agents Med. Chem., 2009, 9,613.
V. M. Moreira, J. A. Salvador, T. S. Vasaitis, V. C. Njar, Curr. Med. Chem., 2008, 15,868.
J. A. Salvador, R. M. Pinto, S. M. Silvestre, J. Steroid Biochem. Mol. Biol., 2013, 137,199.
J. A. Salvador, V. M. Moreira, S. M. Silvestre, in Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic. Advances in Prostate Cancer, Intech, 2013, p.275.
O. O. Clement, C. M. Freeman, R. W. Hartmann, V. D. Handratta, T. S. Vasaitis, A. M. Brodie, V. C. Njar, J. Med. Chem., 2003, 46, 2345.
R. Li, K. Evaul, K. K. Sharma, K. H. Chang, J. Yoshimoto, J. Liu, R. J. Auchus, N. Sharifi, Clin. Cancer Res., 2012, 18, 3571.
H. S. Soifer, N. Souleimanian, S. Wu, A. M. Voskresenskiy, F. K. Collak, B. Cinar, C. A. Stein, J. Biol. Chem., 2012, 287, 3777.
J. Richards, A. C. Lim, C. W. Hay, A. E. Taylor, A. Wingate, K. Nowakowska, C. Pezaro, S. Carreira, J. Goodall, W. Arlt, I. J. McEwan, J. S. de Bono, G. Attard, Cancer Res., 2012, 72, 2176.
H. Grossebrummel, T. Peter, R. Mandelkow, M. Weiss, D. Muzzio, U. Zimmermann, R. Walther, F. Jensen, C. Knabbe, M. Zygmunt, M. Burchardt, M. B. Stope, Int. J. Oncol., 2016, 48,793.
R. D. Bruno, T. D. Gover, A. M. Burger, A. M. Brodie, V. C. Njar, Mol. Cancer Ther., 2008, 7, 2828.
R. D. Bruno, T. S. Vasaitis, L. K. Gediya, P. Purushottamachar, A. M. Godbole, Z. Ates-Alagoz, A. M. Brodie, V. C. Njar, Steroids, 2011, 76, 1268.
E. Djurendic, J. Daljev, M. Sakac, J. Canadi, S. J. Šanta, S. Andric, O. Klisuric, V. Kojic, G. Bogdanovic, M. Djurendic-Brenesel, S. Novakovic, K. P. Gaši, Steroids, 2008, 73,129.
E. A. Djurendic, J. J. Ajdukovic, M. N. Sakac, J. J. Csanádi, V. V. Kojic, G. M. Bogdanovic, K. M. Penov Gaši, Eur. J. Med. Chem., 2012, 54,784.
J. J. Ajdukovic, E. A. Djurendic, E. T. Petri, O. R. Klisuric, A. S. Celic, M. N. Sakac, D. S. Jakimov, K. M. Gaši, Bioorg. Med. Chem., 2013, 21, 7257.
S. V. Stulov, Y. V. Tkachev, R. A. Novikov, M. G. Zavialova, V. P. Timofeev, A. Y. Misharin, Steroids, 2012, 77,77.
S. V. Stulov, O. V. Mankevich, R. A. Novikov, Y. V. Tkachev, V. P. Timofeev, N. O. Dugin, V. F. Pozdnev, I. V. Fedyushkina, D. S. Scherbinin, A. V. Veselovsky, A. Y. Misharin, Steroids, 2013, 78,521.
V. A. Kostin, V. A. Zolottsev, A. V. Kuzikov, R. A. Masa mrekh, V. V. Shumyantseva, A. V. Veselovsky, S. V. Stulov, R. A. Novikov, V. P. Timofeev, A. Y. Misharin, Steroids, 2016, 115,114.
A. V. Kuzikov, N. O. Dugin, S. V. Stulov, D. S. Shcherbinin, M. S. Zharkova, Y. V. Tkachev, V. P. Timofeev, A. V. Veselovsky, V. V. Shumyantseva, A. Y. Misharin, Steroids, 2014, 88,66.
N. Szabó, J. Ajdukovic, E. Djurendic, M. Sakac, I. Ignáth, J. Gardi, G. Mahmoud, O. Klisuric, S. Jovanovic-Šanta, K. Penov Gaši, M. Szécsi, Acta Biol. Hung., 2015, 66,41.
V. A. Zolottsev, V. A. Kostin, R. A. Novikov, Ya. V. Tkachev, M. G. Zav´yalova, M. O. Taratynova, A. S. Latysheva, O. V. Zazulina, V. P. Timofeev, A. Yu. Misharin, Russ. Chem. Bull., 2018, 67,667.
T. A. Pechurskaya, O. P. Lukashevich, A. A. Gilep, S. A. Usanov, Biochemistry (Moscow), 2008, 73,806.
V. Zoete, M. A. Cuendet, A. Grosdidier, O. Michielin, J. Comput. Chem., 2011, 32, 2359.
K. Shahrokh, A. Orendt, G. Yost, T. Cheatham, J. Comput. Chem., 2012, 33,119.
W. Humphrey, A. Dalke, K. Schulten, J. Mol. Graph., 1996, 14,33.
J. C. Phillips, R. Braun, W. Wang, J. Gumbart, E. Tajkhorshid, E. Villa, C. Chipot, R. D. Skeel, L. Kalé, K. Schulten, J. Comput. Chem., 2005, 26, 1781.
T. Mosmann, J. Immunol. Methods, 1983, 65,55.
V. V. Shumyantseva, T. V. Bulko, Y. O. Rudakov, G. P. Kuznetsova, N. F. Samenkova, A. V. Lisitsa, I. I. Karuzina, A. I. Archakov, J. Inorg. Biochem., 2007, 101,859.
V. V. Shumyantseva, T. V. Bulko, E. V. Suprun, Y. M. Chalenko, M. Y. Vagin, Y. O. Rudakov, M. A. Shatskaya, A. I. Archakov, Biochim. Biophys. Acta, 2011, 1814,94.
V. V. Shumyantseva, T. V. Bulko, A. Y. Misharin, A. I. Archakov, Biochemistry (Moscow), Suppl. Series B. Med. Chem., 2011, 5,55.
K. P. Conner, C. Woods, W. M. Atkins, Arch. Biochem. Biophys., 2011, 507, 56.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published in Russian in Izvestiya Akademii Nauk. Seriya Khimicheskaya, No. 4, pp. 0682–0687, April, 2018.
Based on the materials of the III Interdisciplinary Symposium on Medicinal, Organic, and Biological Chemistry and Pharmaceuticals (MOBI-ChemPharm-2017; May 28–31, 2017; Sevastopol, Russia).
Rights and permissions
About this article
Cite this article
Kostin, V.A., Latysheva, A.S., Zolottsev, V.A. et al. Oxazoline derivatives of [17(20)E]-21-norpregnene – inhibitors of CYP17A1 activity and proliferation of prostate carcinoma cells. Russ Chem Bull 67, 682–687 (2018). https://doi.org/10.1007/s11172-018-2122-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11172-018-2122-7